Cellulose nanofibrils (CNFs) hold immense potential across industries, yet their commercialization remains hindered by energy-intensive production processes and reliance on costly, purified pulp feedstocks.
Luan et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: